Novartis Nears Acquisition of Cytokinetics Following Biotech's Heart Disease Breakthrough
TL;DR
Novartis is reportedly in talks to acquire Cytokinetics, with the potential deal expected to be finalized by the end of the week, following Cytokinetics' release of positive Phase III data for its heart disease program, aficamten, which has sparked M&A speculation and caused Cytokinetics' stock to surge nearly 15%.
Topics:businessbusiness-pharmaceuticals#acquisition#biotech#business-pharmaceuticals#cytokinetics#heart-disease#novartis
- Updated: Novartis close to acquiring Cytokinetics after biotech's PhIII heart disease win — WSJ Endpoints News
- Novartis in Advanced Talks to Buy Cytokinetics - WSJ The Wall Street Journal
- Novartis in advanced talks to buy Cytokinetics- source Reuters
- Biotech Claws Back 105% Over A Week. Now It Could Score A Buyout. Investor's Business Daily
Want the full story? Read the original reporting
Read on Endpoints News